Novo Nordisk reported that its next‑generation obesity candidate CagriSema failed to show noninferiority to Eli Lilly’s Zepbound in a head‑to‑head Phase 3 study, weighing on the company’s market position. The REDEFINE 4 trial produced lower weight‑loss outcomes for Novo’s combo versus Lilly’s tirzepatide in the study population. In direct response to competitive pressure and pricing dynamics across the GLP‑1 market, Novo announced plans to cut list prices of its GLP‑1 medicines starting in 2027—reductions of up to roughly 50% for some branded products. Company commentary framed the price move as an effort to ease access for patients with high deductibles while executives argued the CagriSema label would remain commercially meaningful despite the head‑to‑head loss.